Dual orexin antagonist treatment to prevent the neurobehavioral sequelae of TBI
Active Project Grant Awarded Last action
- Award ID
- HT94252310200
- Recipient
-
University Of Wisconsin System UEI LCLSJAGTNZQ7 Part of University Of Wisconsin System
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $3,755,144
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 89% complete
- Place of performance
- Madison, WI 53715, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded a $3.755 million Project Grant to the University of Wisconsin-Madison through the Military Medical Research and Development program (CFDA 12.420) to investigate dual orexin antagonist treatment to prevent neurobehavioral sequelae of traumatic brain injury from April 1, 2023 to March 31, 2027. The Military Medical Research and Development program supports innovative medical research to improve warfighter health and transform public healthcare. Under this award, the University of Wisconsin-Madison will conduct research into using dual orexin antagonists to prevent long-term neurological and behavioral issues that can result from traumatic brain injuries sustained in military service or elsewhere. The University will leverage its expertise in neuroscience and pharmacology to investigate potential medical solutions for traumatic brain injury under the guidance of the Defense Health Agency program.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Beloit College | $70,136 |
Quick answers
Who received award HT94252310200?
HT94252310200 was awarded to University Of Wisconsin System by Defense Health Agency (Department of Defense) on April 1, 2023.
How much is award HT94252310200 worth?
$3,755,144 has been obligated on HT94252310200.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award